Literature DB >> 19530506

Ophthalmological aspects of IBD.

C Manganelli1, S Turco, E Balestrazzi.   

Abstract

Ocular manifestations occur in 4-12% of patients with IBD. Uveitis and iritis are more frequently associated with ulcerative colitis while episcleritis is more common in Crohn's disease. Some ocular manifestations in IBD can be secondary to treatment and/or effects of the intestinal disease itself. The specific management of ocular manifestations in IBD requires the use of topical steroids and FANS, cycloplegics, systemic steroids or immunosuppressive drugs. When conventional therapies fail to control the ocular manifestations in IBD, the new biologic drugs can be considered as good alternative treatments. Early diagnosis and effective treatment may avoid the onset of severe and sometimes persisting complications. In some cases, a surgical approach is required to treat eye complications, i.e. cataract, and to improve the patient's quality of life.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19530506

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  Ocular Manifestations in Inflammatory Bowel Disease Are Associated with Other Extra-intestinal Manifestations, Gender, and Genes Implicated in Other Immune-related Traits.

Authors:  Sasha Taleban; Dalin Li; Stephan R Targan; Andrew Ippoliti; Steven R Brant; Judy H Cho; Richard H Duerr; John D Rioux; Mark S Silverberg; Eric A Vasiliauskas; Jerome I Rotter; Talin Haritunians; David Q Shih; Marla Dubinsky; Gil Y Melmed; Dermot P B McGovern
Journal:  J Crohns Colitis       Date:  2015-10-08       Impact factor: 9.071

2.  Decreased retinal blood flow in experimental colitis; improvement by eye drop administration of losartan.

Authors:  Megan N Watts; Randa S Eshaq; Patsy R Carter; Norman R Harris
Journal:  Exp Eye Res       Date:  2013-07-02       Impact factor: 3.467

3.  Prevalence and characteristics of ophthalmological extra-intestinal manifestations in Chinese patients with inflammatory bowel disease.

Authors:  Ying-Chao Li; Wei-Zhi Li; Chang-Rui Wu; Yun Feng; Li Ren; Chen Mi; Yang Li
Journal:  Int J Ophthalmol       Date:  2016-10-18       Impact factor: 1.779

4.  Ocular dysfunction in a mouse model of chronic gut inflammation.

Authors:  Megan N Watts; Wendy Leskova; Patsy R Carter; Songlin Zhang; Melissa Kosloski-Davidson; Matthew B Grisham; Norman R Harris
Journal:  Inflamm Bowel Dis       Date:  2013-09       Impact factor: 5.325

Review 5.  Targeting NF-κB pathway for treating ulcerative colitis: comprehensive regulatory characteristics of Chinese medicines.

Authors:  Peng-De Lu; Yong-Hua Zhao
Journal:  Chin Med       Date:  2020-02-10       Impact factor: 5.455

6.  Small intestine inflammation in Roquin-mutant and Roquin-deficient mice.

Authors:  Jeremy S Schaefer; Dina Montufar-Solis; Niyati Nakra; Nadarajah Vigneswaran; John R Klein
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.